Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

CTAD 2022 | Photobiomodulation: why target the brain and the gut?

Jacques Touchon, MD, PhD, University Hospital of Montpellier, Montpellier, France, presents the rationale behind investigating brain-gut photobiomodulation (PBM) in the treatment of Alzheimer’s disease (AD). REGEnLIFE RGn600 is a medical device that administers PBM via a helmet and belt to the brain and abdomen, respectively. Growing interest in the interactions between the brain and the gut, specifically regarding inflammation, propelled Prof. Touchon and his team to administer PBM in this way. He particularly notes that he believes AD treatment should expand further than targeting amyloid and tau, which also contributed to the design of this therapy. This interview took place at the Clinical Trials on Alzheimer’s Disease Congress 2022 in San Francisco.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Prof. Touchon reports the following disclosures:
-REGEnLIFE stockholder